MBIO — Mustang Bio Cashflow Statement
0.000.00%
Last trade - 00:00- $3.60m
- -$3.24m
Annual cashflow statement for Mustang Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -60 | -66.4 | -77.5 | -51.6 | -15.8 |
| Depreciation | |||||
| Non-Cash Items | 17.9 | 11.2 | 5.71 | 3.02 | 4.61 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.09 | -0.637 | 4.03 | -2.76 | -0.942 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -37.3 | -53.7 | -65.1 | -49.5 | -11.4 |
| Capital Expenditures | -1.93 | -3.99 | -2.71 | -0.064 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -2.49 | -1.38 | -0.238 | 5.95 | 0 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -4.41 | -5.37 | -2.95 | 5.89 | 0 |
| Financing Cash Flow Items | -3.51 | -1.38 | -2.77 | -0.445 | -1.46 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 78.1 | 70.8 | 34.1 | -26.1 | 11.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 36.4 | 11.8 | -34 | -69.7 | -0.145 |